FEATURED SESSION
Data quality 2.0: The future of real-world evidence
Monday, May 8, 2023 | 11:45 AM - 12:45 PM ET
This educational symposium focuses on the importance of a modern data quality framework in handling the increasing complexity and diversity of real-world data. Join experts from Flatiron, Bristol Myers Squibb and Takeda explore how a fresh perspective on data quality enhances the impact and applicability of real-world evidence, particularly in value assessments.
Monday, May 8 | 10:15 AM - 11:15 AM ET
RWE and health disparities in HTAs: Is transferability the main barrier for equity data sharing across borders?
This panel will debate the potential of real-world evidence (RWE) to address health disparities in health technology assessments (HTAs) and whether RWE transferability is a significant concern and potential barrier for HTA bodies when deciding whether treatments could undress underlying health disparities.
Flatiron Participant:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Flatiron Participant:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Monday, May 8 | 10:15 AM - 11:15 AM ET
Podium Presentation - Measures of neighborhood structural racism and overall survival among patients with metastatic breast cancer
Click here to learn more about this research.
Flatiron Participant:
Harlan Pittell, PhD, Quantitative Scientist
Flatiron Participant:
Harlan Pittell, PhD, Quantitative Scientist
Monday, May 8 | 11:45 AM - 12:45 AM ET
Data quality 2.0: The future of real-world evidence
This educational symposium focuses on the importance of a data-quality framework in handling the increasing complexity and diversity of real-world data. It will also explore how a fresh perspective on data quality enhances the impact and applicability of real-world evidence, particularly in value assessments.
Flatiron Participants:
Javier Jimenez, MD, MPH, Chief Medical Officer
Emily Castellanos, MD, MPH, Senior Medical Director
Flatiron Participants:
Javier Jimenez, MD, MPH, Chief Medical Officer
Emily Castellanos, MD, MPH, Senior Medical Director
Monday, May 8 | 3:15 PM - 4:15 PM ET
What is an open-source model? Forking a path to definition
This forum session, led by ISPOR’s Open Source Models Special Interest Group, will discuss challenges in defining ‘open-source’ in the context of Health Economics and Outcomes Research (HEOR). The panel will explore the meaning and practical value of open-source in HEOR and different perspectives that ought to be considered.
Flatiron Participant:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Flatiron Participant:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Monday, May 8 | 4:45 PM - 5:45 PM ET
Podium Session - Machine Learning in Outcomes Research
The use of machine learning in outcomes research is becoming more prevalent. This session will present a range of methods utilizing these techniques with actual datasets
Flatiron Participant:
Erin Fidyk, ANP-BC, MBA, Senior Clinical Director, Research Oncology
Flatiron Participant:
Erin Fidyk, ANP-BC, MBA, Senior Clinical Director, Research Oncology
Tuesday, May 9 | 8:30 AM - 10:00 AM ET
AI wants to chat with you: Accept or ignore?
This session will feature insights from notable thought leaders on the broader adoption of artificial intelligence (AI) in healthcare and the potential implications for health economics and outcomes research. The discussion will particularly revolve around whether AI will augment, disrupt, or have a mixed impact on the field.
Flatiron Participant:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Flatiron Participant:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Tuesday, May 9 | 10:15 AM - 11:15 AM ET
Beyond burden of illness - Using RWE for advanced HEOR analytics
This workshop is focused on the potential of using real-world evidence (RWE) beyond descriptive statistics in drug reimbursement decisions. The discussants will share various advanced analytics that can be used with RWE, such as hybrid RWE-enhanced extrapolation and synthetic control arms and potential analytical biases that can be mitigated.
Flatiron Participant:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Flatiron Participant:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Tuesday, May 9 | 11:45 AM - 12:45 PM ET
Assessing real-world data from electronic health records (EHRs) for HTA
This research is focused on establishing best practices for using and interpreting electronic health record-derived real-world data in health technology assessments. The task force will address data quality frameworks, guidelines from NICE, ICER, CADTH, and limitations like privacy, consent, and funding. They will also discuss future directions for the field.
Flatiron Participants:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Seamus Kent, PhD, MSc, Senior Adviser, HTA and Market Access
Flatiron Participants:
Blythe Adamson, PhD, MPH, Principal Quantitative Scientist, RWE Engagement
Seamus Kent, PhD, MSc, Senior Adviser, HTA and Market Access
Tuesday, May 9 | 1:45 PM - 2:45 PM ET
Larger, deeper, and in real time: Applications of machine learning and natural language processing on electronic health records to learn from the patient journey at scale
This research is focused on the role of real-world data (RWD) information systems in precision medicine, especially for smaller populations and evolving standards of care. Large-scale RWD is needed to identify at-risk groups, address care disparities, and understand outcomes for rare biomarkers. Advanced techniques like machine learning (ML) and natural language processing (NLP) enable real-time, scalable insights without manual curation. This session will focus on case studies where ML/NLP is applied to EHRs to obtain RWD and real-world evidence quickly and at scale.
Flatiron Participant:
Katherine Tan, PhD, Senior Quantitative Scientist, Machine Learning
Flatiron Participant:
Katherine Tan, PhD, Senior Quantitative Scientist, Machine Learning
Wednesday, May 10 | 8:00 AM - 9:00 AM ET
Routing RWE sources in HTA submissions when standard of care is not established: How to robustly validate your uncertainties
This workshop will discuss the challenges of health technology assessments (HTA) when direct comparative clinical data is lacking and how real-world evidence (RWE) can be used to address this evidence gap. The discussion will include two recent NICE submissions as case studies for audience participation and perspectives on how current RWE frameworks could guide RWE decisions and HTA submissions.
Flatiron Participant:
Seamus Kent, PhD, MSc, Senior Adviser, HTA and Market Access
Flatiron Participant:
Seamus Kent, PhD, MSc, Senior Adviser, HTA and Market Access
Raina Mathur, MS
Senior Quantitative Scientist
Monday, May 8 | 9:45 AM - 10:15 AM
Raina leverages her expertise in fit-for-purpose real-world data (RWD) to partner with life sciences companies in generating real-world evidence for clinical development, market access, and commercial use cases. Her recent collaborations have culminated in publications that focus on complementing and supplementing clinical trial data with RWD to generate findings in underrepresented patient groups.
Talk to me about: Developing fit-for-purpose real-world data and analytic services offerings for outcomes research in oncology
Emily Castellanos, MD, MPH
Senior Medical Director
Monday, May 8 | 2:45 PM - 3:15 PM
Emily leverages her clinical and research expertise to develop innovative approaches to real-world evidence generation and inform product strategy. Her interests include integrated approaches to real-world data, such as clinico-genomics, clinico-claims, or imaging data, as well as novel approaches to real-world study design. In addition to her role at Flatiron, Emily maintains a clinical practice specializing in breast malignancies at Fox Chase Cancer Center.
Talk to me about: Health outcomes research in oncology, real-world data quality, integrated evidence
Wendy (Xiaoliang) Wang, PhD
Senior Quantitative Scientist
Tuesday, May 9 | 9:45 AM - 10:15 AM
Wendy works closely with academic investigators in various topics of treatment patterns, health outcomes, quality of care and health equity research, by leveraging contemporary real-world evidence. She has also led evaluations in leveraging RWD to enhance survival extrapolation. Her work has been published in JAMA Oncology, JAMA Network Open, Cancer, CEBP, JCO CCI and Value in Health.
Talk to me about: Health outcomes research, methodology considerations in real-world evidence
Samantha Reiss, PharmD, BCOP
Clinical Director
Monday, May 8 | 9:45 AM - 10:15 AM
Samantha is a Board Certified Oncology Pharmacist working as a Clinical Director of Research Oncology, Real-World Evidence team at Flatiron. Prior to joining Flatiron, Samantha worked at Memorial Sloan Kettering as an Oncology Clinical Pharmacy Specialist working with the Neuro-Oncology team. Her interests include claims research, solid tumors, treatment of brain metastases, and immuno-oncology.
Talk to me about: EHR-claims linkage, solid malignancies, adverse events, brain metastases treatment
Katherine Tan, PhD
Senior Quantitative Scientist
Monday, May 8 | 2:45 PM - 3:15 PM
Katherine has published extensively in the topics of biostatistics, biomedical natural language processing (NLP) and real-world evidence in oncology. Her work has appeared in top academic conferences and journals such as Biostatistics, Clinical Pharmacology & Therapeutics, ISPOR, and Value of Health; and she has organized and spoken at panels (ENAR) and podcasts (ResearchX) on RWE.
Talk to me about: ML & NLP and their usages in health outcomes research and biopharma applications
Christina Fullerton, PharmD, BCOP
Clinical Director
Tuesday, May 9 | 2:45 PM - 3:15 PM
Christina is a board-certified oncology pharmacist working as a Clinical Director of Research Oncology on the Real-World Evidence team at Flatiron. Prior to this role she worked as an Oncology Clinical Pharmacy Specialist at Overlook Medical Center in both hematologic malignancies and medical oncology services. Her research interests include double-hit lymphoma, chronic lymphocytic leukemia, and myeloid malignancies.
Talk to me about: Real-world evidence generation and real-world endpoints development in hematologic malignancies
Gregory Calip, PharmD, MPH, PhD
Principal Quantitative Scientist
Monday, May 8 | 2:45 PM - 3:15 PM
Greg is a nationally recognized expert in pharmacoepidemiology and health equity research, and has published research and editorials extensively on these topics related to breast cancer and hematological malignancies. At Flatiron, Greg works with the Academic and Health Systems Partnerships team and in the Research Unit on applied health equity research investments and collaborations with the FDA.
Talk to me about: Pharmacoepidemiology, pharmacovigilance, health equity research, social determinants of health, clinical trial diversity and representativeness
Harlan Pittell, PhD
Quantitative Scientist
Tuesday, May 9 | 9:45 AM - 10:15 AM
Harlan helps to deliver real-world evidence to Flatiron clients and utilizes Flatiron's EHR-derived databases to generate new insights on health inequities in the United States among patients with cancer. Before joining Flatiron, Harlan completed his PhD in health policy and management from the Johns Hopkins Bloomberg School of Public Health, where he assessed the benefits of EHR data.
Talk to me about: EHR data, health technology assessments, health equity research, racial/ethnic inequities in oncology trial participation
Seamus Kent, PhD
Senior Advisor, HTA & Market Access
Tuesday, May 9 | 2:45 PM - 3:15 PM
Seamus is a health economist and statistician with extensive experience in health technology assessment (HTA), market access, and real-world data. At Flatiron, Seamus is leading collaborative research projects to demonstrate the value of real-world evidence in HTA and supporting the development of US and International data products. Before joining Flatiron, Seamus led the development of NICE’s RWE framework.
Talk to me about: Health technology assessment, international real-world data products